{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:19:09Z","timestamp":1784729949206,"version":"3.55.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1462,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T00:00:00Z","timestamp":1638576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Although diabetes mellitus (DM) is a common co-morbidity in chronic heart failure (HF) patients, European data on concurrent HF and DM treatment are lacking. Therefore, we have studied the HF treatment of patients with and without DM. Additionally, with the recent breakthrough of sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors in the field of HF, we studied the potential impact of this new drug in a large cohort of HF patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A total of 7488 patients with chronic HF with a left ventricular ejection fraction &amp;lt;50% from 34 Dutch outpatient HF clinics between 2013 and 2016 were analysed on diabetic status and background HF therapy. Average age of the total population was 72.8 years (\u00b111.7 years), and 64% of the patients were male. Diabetes was present in 29% of the patients (N = 2174). Diabetics had a worse renal function (mean estimated glomerular filtration rate 56 vs. 61 mL\/min\/1.73 m2, P &amp;lt; 0.001). Renin\u2013angiotensin system inhibitors were less often prescribed in diabetics compared with non-diabetics (79% vs. 82%, P = 0.001), while no significant differences regarding other guideline-recommended HF drugs were found. Target doses of beta-blockers (23% vs. 16%, P &amp;lt; 0.001), renin\u2013angiotensin system inhibitors (47% vs. 43%, P = 0.009), and mineralocorticoid receptor antagonists (57% vs. 51%, P = 0.005) were more often prescribed in diabetics than non-diabetics. Based on the latest trials on SGLT2 inhibitors, 31\u201364% of all HF patients would fulfil the eligibility or enrichment criteria (with vs. without N-terminal prohormone BNP criterion).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large real-world HF registry, a high prevalence of DM was observed and diabetics more often received guideline-recommended target doses. Based on current evidence, the majority of patients would fulfil the enrichment criteria of SGLT2 trials in HF and the impact of this new drug class will be large.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13743","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T03:50:49Z","timestamp":1638589849000},"page":"353-362","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Diabetes and Treatment of Chronic Heart Failure in a Large Real-World Heart Failure Population"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-6715","authenticated-orcid":false,"given":"Sumant P.","family":"Radhoe","sequence":"first","affiliation":[{"name":"Department of Cardiology, Thorax Center, Erasmus MC, University Medical Center Rotterdam , Dr. Molewaterplein 40, Rotterdam, 3015GD ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse F.","family":"Veenis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thorax Center, Erasmus MC, University Medical Center Rotterdam , Dr. Molewaterplein 40, Rotterdam, 3015GD ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard C.M.","family":"Linssen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Group Twente , Almelo and Hengelo ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"van der Lee","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Streekziekenhuis Koningin Beatrix , Winterswijk ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc W.M.","family":"Eurlings","sequence":"additional","affiliation":[{"name":"Department of Cardiology, VieCuri Medisch Centrum , Venlo ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Kragten","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zuyderland Medisch Centrum , Heerlen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadea Y.Y.","family":"Al-Windy","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Gelre Ziekenhuizen , Zutphen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aukje","family":"van der Spank","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Flevoziekenhuis , Almere ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Koudstaal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Utrecht and Utrecht University , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Brunner-La Rocca","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maastricht University Medical Center , Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper J.","family":"Brugts","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thorax Center, Erasmus MC, University Medical Center Rotterdam , Dr. Molewaterplein 40, Rotterdam, 3015GD ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,4]]},"reference":[{"key":"2026012114185265500_ehf213743-bib-0001","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1161\/CIR.0000000000000450","article-title":"Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association","volume":"134","author":"Bozkurt","year":"2016","journal-title":"Circulation"},{"key":"2026012114185265500_ehf213743-bib-0002","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114185265500_ehf213743-bib-0003","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012114185265500_ehf213743-bib-0004","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jchf.2019.12.015","article-title":"Contemporary treatment patterns and clinical outcomes of comorbid diabetes mellitus and HFrEF: the CHAMP-HF registry","volume":"8","author":"Vaduganathan","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026012114185265500_ehf213743-bib-0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","article-title":"Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF registry","volume":"7","author":"Brunner-La Rocca","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026012114185265500_ehf213743-bib-0006","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006667","article-title":"Treatment differences in chronic heart failure patients with reduced ejection fraction according to blood pressure","volume":"13","author":"Veenis","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026012114185265500_ehf213743-bib-0007","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012114185265500_ehf213743-bib-0008","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s12471-018-1103-7","article-title":"Real-world heart failure management in 10,910 patients with chronic heart failure in the Netherlands: design and rationale of the Chronic Heart failure ESC guideline-based Cardiology practice Quality project (CHECK-HF) registry","volume":"26","author":"Brugts","year":"2018","journal-title":"Neth Heart J"},{"key":"2026012114185265500_ehf213743-bib-0009","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"2026012114185265500_ehf213743-bib-0010","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.1536","article-title":"Evaluation of the effect of sodium\u2013glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial","volume":"21","author":"Packer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114185265500_ehf213743-bib-0011","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1177\/2047487319835042","article-title":"Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction","volume":"26","author":"Veenis","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2026012114185265500_ehf213743-bib-0012","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1185\/030079906X80459","article-title":"The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis","volume":"22","author":"Bell","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"2026012114185265500_ehf213743-bib-0013","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ahj.2004.05.056","article-title":"Efficacy, safety and tolerability of metoprolol CR\/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF","volume":"149","author":"Deedwania","year":"2005","journal-title":"Am Heart J"},{"key":"2026012114185265500_ehf213743-bib-0014","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012114185265500_ehf213743-bib-0015","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur Heart J"},{"key":"2026012114185265500_ehf213743-bib-0016","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0735-1097(03)00262-6","article-title":"Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials","volume":"41","author":"Shekelle","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026012114185265500_ehf213743-bib-0017","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"2026012114185265500_ehf213743-bib-0018","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00392-007-0571-3","article-title":"Effect of selective and non-selective \u03b2-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure","volume":"97","author":"Kovacic","year":"2008","journal-title":"Clin Res Cardiol"},{"key":"2026012114185265500_ehf213743-bib-0019","article-title":"Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control","volume":"14","author":"Wai","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"2026012114185265500_ehf213743-bib-0020","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/01.CIR.0000054611.89228.92","article-title":"Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD)","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"key":"2026012114185265500_ehf213743-bib-0021","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.104.528166","article-title":"Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure","volume":"112","author":"Yusuf","year":"2005","journal-title":"Circulation"},{"key":"2026012114185265500_ehf213743-bib-0022","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurjhf\/hfs067","article-title":"Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"14","author":"Preiss","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026012114185265500_ehf213743-bib-0023","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am Heart J"},{"key":"2026012114185265500_ehf213743-bib-0024","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.hfc.2008.03.008","article-title":"Epidemiology of chronic kidney disease in heart failure","volume":"4","author":"Ahmed","year":"2008","journal-title":"Heart Fail Clin"},{"key":"2026012114185265500_ehf213743-bib-0025","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002638","article-title":"Antihyperglycemic medication use among Medicare beneficiaries with heart failure, diabetes mellitus, and chronic kidney disease","volume":"9","author":"Patel","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026012114185265500_ehf213743-bib-0026","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cardfail.2007.03.011","article-title":"High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database","volume":"13","author":"Heywood","year":"2007","journal-title":"J Card Fail"},{"key":"2026012114185265500_ehf213743-bib-0027","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ejhf.226","article-title":"Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case\u2013control study in UK general practice","volume":"17","author":"Michel","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012114185265500_ehf213743-bib-0028","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2174\/1573403X12666160606120254","article-title":"Type 2 diabetes and heart failure: challenges and solutions","volume":"12","author":"Thomas","year":"2016","journal-title":"Curr Cardiol Rev"},{"key":"2026012114185265500_ehf213743-bib-0029","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114185265500_ehf213743-bib-0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijcard.2016.02.130","article-title":"The PARADIGM of ARNI's: assessing reasons for non-implementation in heart failure","volume":"212","author":"Lainscak","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026012114185265500_ehf213743-bib-0031","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114185265500_ehf213743-bib-0032","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ejhf.788","article-title":"What proportion of patients with chronic heart failure are eligible for sacubitril\u2013valsartan?","volume":"19","author":"Pellicori","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012114185265500_ehf213743-bib-0033","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114185265500_ehf213743-bib-0034","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012114185265500_ehf213743-bib-0035","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13743","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13743","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/1\/353\/65375068\/eschf_9_1_353.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/1\/353\/65375068\/eschf_9_1_353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:22:23Z","timestamp":1769023343000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/1\/353\/8326399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,4]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,4]]},"published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13743","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2]]},"published":{"date-parts":[[2021,12,4]]},"assertion":[{"value":"2021-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}